{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:54:06Z","timestamp":1648533246061},"reference-count":28,"publisher":"Akademiai Kiado Zrt.","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>Introduction: Thrombo-haemorrhagic complications contribute to both morbidity and mortality in patients with essential thrombocythaemia. Aim: The aim of the authors was to estimate the incidence of thrombotic events and to examine the clinical utility of IPSET thrombosis risk evaluation score against conventional two-categorical (low and high) risk assessment. Method: A retrospective analysis was carried out on 155 patients with essential thrombocythaemia (106 females; median age, 61 years) in a period between 1999 and 2014. Results: The analysis revealed 55 (35.5%) major thrombotic events before and 25 (16.1%) major thrombotic complications after establishment of the haematologic diagnosis. Significant differences were observed in thrombosis-free survival between the different IPSET groups (p = 0.002). Conclusions: The IPSET model was first examined in this cohort of patients with essential thrombocythaemia diagnosed in a single Hungarian haematologic centre. The results suggest that this score may provide more information than the conventional thrombosis risk assessment. Orv. Hetil., 2015, 156(14), 558\u2013563.<\/jats:p>","DOI":"10.1556\/oh.2015.30117","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T01:01:28Z","timestamp":1427677288000},"page":"558-563","source":"Crossref","is-referenced-by-count":1,"title":["Thrombotic events and importance of IPSET thrombosis risk evaluation score in essential thrombocythaemia"],"prefix":"10.1556","volume":"156","author":[{"given":"\u00c9va","family":"P\u00f3sfai","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont, Haematol\u00f3giai Oszt\u00e1ly Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imelda","family":"Marton","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont, Haematol\u00f3giai Oszt\u00e1ly Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Nemes","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont Szeged Semmelweis utca 6. 6720"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Borb\u00e9nyi","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont, Haematol\u00f3giai Oszt\u00e1ly Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"<i>Barbui, T., Thiele, J., Passamonti, F., et al.:<\/i> Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol., 2011, <i>29<\/i>(23), 3179\u20133184.","DOI":"10.1200\/JCO.2010.34.5298"},{"key":"2","doi-asserted-by":"crossref","unstructured":"<i>Chim, C. S., Kwong, Y. L., Lie, A. K., et al.:<\/i> Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch. Intern. Med., 2005, <i>165<\/i>(22), 2651\u20132658.","DOI":"10.1001\/archinte.165.22.2651"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A., Vardiman, J. W.:<\/i> Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008, <i>22<\/i>(1), 14\u201322.","DOI":"10.1038\/sj.leu.2404955"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A.:<\/i> Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 2013, <i>88<\/i>(6), 507\u2013516.","DOI":"10.1002\/ajh.23417"},{"key":"5","doi-asserted-by":"crossref","unstructured":"<i>Falanga, A., Marchetti, M.:<\/i> Thrombotic disease in the myeloproliferative neoplasms. Hematology Am. Soc. Hematol. Educ. Program, 2012, <i>2012,<\/i> 571\u2013581.","DOI":"10.1182\/asheducation.V2012.1.571.3798557"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A.:<\/i> Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol., 2012, <i>87<\/i>(3), 285\u2013293.","DOI":"10.1002\/ajh.23135"},{"key":"7","doi-asserted-by":"crossref","unstructured":"<i>Hermanns, B., Handt, S., Kindler, J., et al.:<\/i> Coronary vasculopathy in polycythemia vera. Pathol. Oncol. Res., 1998, <i>4<\/i>(1), 37\u201339.","DOI":"10.1007\/BF02904693"},{"key":"8","unstructured":"<i>Barbui, T., Barosi, G., Grossi, A., et al.:<\/i> Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2004, <i>89<\/i>(2), 215\u2013232."},{"key":"9","unstructured":"<i>Lehoczky, D.<\/i> (ed.): Current treatment of hematologic diseases \u2013 Treatment guideline of the Hungarian Professional Commission of Transfusion and Hematology and Scientific Society. [Hematol\u00f3giai betegs\u00e9gek korszer\u0171 kezel\u00e9se \u2013 A Magyar Transzfuziol\u00f3giai \u00e9s Hematol\u00f3giai Szakmai Koll\u00e9gium \u00e9s a Tudom\u00e1nyos T\u00e1rsas\u00e1g kezel\u00e9si ir\u00e1nyelvei.] Zafir Press, Budapest, 2011. [Hungarian]"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Birgeg\u00e5rd, G.:<\/i> Pharmacological management of essential thrombocythemia. Expert Opin. Pharmacother., 2013, <i>14<\/i>(10), 1295\u20131306.","DOI":"10.1517\/14656566.2013.797408"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Barbui, T., Finazzi, G., Carobbio, A., et al.:<\/i> Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET\u2013thrombosis). Blood, 2012, <i>120<\/i>(26), 5128\u20135133.","DOI":"10.1182\/blood-2012-07-444067"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Barbui, T., Barosi, G., Birgegard, G., et al.:<\/i> Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol., 2011, <i>29<\/i>(6), 761\u2013770.","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Carobbio, A., Thiele, J., Passamonti, F., et al.:<\/i> Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 2011, <i>117<\/i>(22), 5857\u20135859.","DOI":"10.1182\/blood-2011-02-339002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A., Barbui, T.:<\/i> Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am. J. Hematol., 2015, <i>90<\/i>(2), 162\u2013173.","DOI":"10.1002\/ajh.23895"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A., Elliott, M.:<\/i> Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin. Thromb. Hemost., 2007, <i>33<\/i>(4), 313\u2013320.","DOI":"10.1055\/s-2007-976165"},{"key":"16","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A., Barbui, T.:<\/i> Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia, 2013, <i>27<\/i>(8), 1617\u20131620.","DOI":"10.1038\/leu.2013.99"},{"key":"17","doi-asserted-by":"crossref","unstructured":"<i>Lee, H. S., Park, L. C., Lee, E. M., et al.:<\/i> Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin. Lymphoma Myeloma Leuk., 2012, <i>12<\/i>(1), 70\u201375.","DOI":"10.1016\/j.clml.2011.10.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"<i>Andrikovics, H., Meggyesi, N., Szilvasi, A., et al.:<\/i> HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer Epidemiol. Biomarkers Prev., 2009, <i>18<\/i>(3), 929\u2013934.","DOI":"10.1158\/1055-9965.EPI-08-0359"},{"key":"19","doi-asserted-by":"crossref","unstructured":"<i>Palandri, F., Polverelli, N., Catani, L., et al.:<\/i> Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann. Hematol., 2011, <i>90<\/i>(8), 933\u2013938.","DOI":"10.1007\/s00277-010-1154-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"<i>Gangat, N., Wolanskyj, A. P., Schwager, S. M., et al.:<\/i> Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer, 2009, <i>115<\/i>(24), 5740\u20135745.","DOI":"10.1002\/cncr.24664"},{"key":"21","doi-asserted-by":"crossref","unstructured":"<i>Tefferi, A.:<\/i> Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms\u2013biologically plausible but clinically uncertain. Am. J. Hematol., 2010, <i>85<\/i>(2), 93\u201394.","DOI":"10.1002\/ajh.21614"},{"key":"22","doi-asserted-by":"crossref","unstructured":"<i>Barbui, T., Carobbio, A., Rambaldi, A., et al.:<\/i> Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, 2009, <i>114<\/i>(4), 759\u2013763.","DOI":"10.1182\/blood-2009-02-206797"},{"key":"23","doi-asserted-by":"crossref","unstructured":"<i>Cazzola, M., Kralovics, R.:<\/i> From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 2014, <i>123<\/i>(24), 3714\u20133719.","DOI":"10.1182\/blood-2014-03-530865"},{"key":"24","doi-asserted-by":"crossref","unstructured":"<i>Finazzi, G., De Stefano, V., Barbui, T.:<\/i> Are MPNs vascular diseases? Curr. Hematol. Malig. Rep., 2013, <i>8<\/i>(4), 307\u2013316.","DOI":"10.1007\/s11899-013-0176-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"<i>Passamonti, F., Caramazza, D., Mora, B.:<\/i> It is time to change thrombosis risk assessment for PV and ET? Best Pract. Res. Clin. Haematol., 2014, <i>27<\/i>(2), 121\u2013127.","DOI":"10.1016\/j.beha.2014.07.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"<i>Andrikovics, H., Szilv\u00e1si, A., Meggyesi, N., et al.:<\/i> Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection. [A 2-es t\u00edpus\u00fa Janus tirozin kin\u00e1z Val617Phe aktiv\u00e1l\u00f3 pontmut\u00e1ci\u00f3 szerepe \u00e9s kimutat\u00e1s\u00e1nak jelent\u0151s\u00e9ge myeloproliferat\u00edv szindr\u00f3m\u00e1ban.] Orv. Hetil., 2007, <i>148<\/i>(5), 203\u2013210. [Hungarian]","DOI":"10.1556\/OH.2007.27860"},{"key":"27","doi-asserted-by":"crossref","unstructured":"<i>Baxter, E. J., Scott, L. M., Campbell, P. J., et al.:<\/i> Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, <i>365<\/i>(9464), 1054\u20131061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"<i>Fu, R., Xuan, M., Lv, C., et al.:<\/i> External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. Eur. J. Haematol., 2014, <i>92<\/i>(6), 502\u2013509.","DOI":"10.1111\/ejh.12275"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2015.30117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T08:12:30Z","timestamp":1598861550000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2015.30117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1556\/OH.2015.30117"],"URL":"https:\/\/doi.org\/10.1556\/oh.2015.30117","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}